Scientists have developed a new approach for the treatment of asthma and allergies

British scientists create to fill a whole new class of drugs against asthma and allergies. They found the target for the drug, the effects on the onset of symptoms will prevent. By The Journal of Immunology Scientists from the Medical and Dental School, Barts and London (Barts and the London School of Medicine and Dentistry) conducted their research in vitro and in mice. In experiments in cell cultures, it confirms the theory that the two molecules from the family of the phosphatidylinositol 3-kinase (phosphoinositide 3-kinase (PI3-K)) - p110-p110 delta and gamma - in the initiation of the immune response involved, are controlling cell degranulation of mast cells. However, tests on mice showed that a central role in this process, the p110 delta, the head of research Vanhazebruk Bart (Bart Vanhaesebroeck) is. Asthma and allergies are very common. In the UK alone more than 30% of the people some kind of allergy and approximately five million people suffer from asthma. Most treatments for these diseases are on target withdrawal symptoms, particularly itchy eyes and runny nose. There are also medications that suppress the immune system, but their use increases the risk for infections. Medications that the molecule p110 delta block, the development of an allergic response to the onset of symptoms to stop, and at the same time does not suppress the immune system, said Vanhazebruk. Moreover, these means in the form of capsules or inhalers are made, and not only in injections. Currently, scientists are busy these products. After Vanhazebruka to open them interested in the major pharmaceutical companies. "We hope that the drugs for people in the near future to be created, this approach offers the potential for the creation of asthma and allergy drugs that act on the root causes, not just the symptoms." - Said the scientist.